A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets.
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs Metformin/sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 according to ClinicalTrial.gov record.